NCT03377400 is a Phase 2 clinical trial of Durvalumab in Esophageal Squamous Cell Carcinoma, sponsored by Samsung Medical Center.

Who is sponsoring NCT03377400?

NCT03377400 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03377400?

Interventions in NCT03377400: Durvalumab.

What condition does NCT03377400 study?

NCT03377400 studies Esophageal Squamous Cell Carcinoma.

Is NCT03377400 still recruiting?

NCT03377400 is currently status unknown. Last updated 17 December 2020.

Last reviewed 2020-12-17 · How we verify

NCT03377400

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Status unknown Phase 2 Last updated 17 December 2020

What this trial tests

Phase 2 trial testing Durvalumab in Esophageal Squamous Cell Carcinoma in 40 participants. Status unknown.

Timeline

14 December 2017

Primary endpoint
30 June 2021

30 December 2021

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	14 December 2017
Primary completion	30 June 2021
Estimated completion	30 December 2021
Sites	1 location across South Korea

Drugs / interventions tested

Durvalumab — full drug profile →

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Samsung Medical Center

Who can join

19 and older, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent radiotherapy for inoperable locally advanced esophageal squamous cell carcinoma. Four weeks after completion of CCRT combined with immunotherapy, 2 cycles of durvaluma and tremelimumab will be administered every 4 weeks and thereafter durvalumab monotherapy Q4W will be maintained until unacceptable toxicity or disease progression, or for maximum 2 years after enrollment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment.
Zhang J, Späth SS, Marjani SL, Zhang W, et al · · 2018 · cited 90× · PMID 30687561 · DOI 10.1093/pcmedi/pby007
Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments.
Procureur A, Simonaggio A, Bibault JE, Oudard S, et al · · 2021 · cited 49× · PMID 33567530 · DOI 10.3390/cancers13040678
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer.
Yang H, Wang K, Wang T, Li M, et al · · 2020 · cited 35× · PMID 32195194 · DOI 10.3389/fonc.2020.00300
Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.
Li R, Huang B, Tian H, Sun Z. · · 2022 · cited 33× · PMID 36698392 · DOI 10.3389/fonc.2022.1096717
Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma.
Veigas F, Mahmoud YD, Merlo J, Rinflerch A, et al · · 2021 · cited 30× · PMID 33804419 · DOI 10.3390/cancers13051018
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review.
Zhang W, Wang P, Pang Q. · · 2020 · cited 29× · PMID 33241042 · DOI 10.21037/atm-20-4625
Current status and perspectives of esophageal cancer: a comprehensive review.
Jiang W, Zhang B, Xu J, Xue L, et al · · 2025 · cited 28× · PMID 39723635 · DOI 10.1002/cac2.12645
Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.
Jiao R, Luo H, Xu W, Ge H. · · 2019 · cited 26× · PMID 31551657 · DOI 10.2147/ott.s214579

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03377400 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 17 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03377400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing